Literature DB >> 15498048

Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?

E R Capper1, J K Maskill, C Gordon, A I F Blakemore.   

Abstract

Several cytokines have been implicated individually in the pathogenesis of systemic lupus erythematosus (SLE) and some, including interleukin (IL)-10, IL-12 and IL-1ra are raised during flares of disease activity. Few studies have been directed at examining the interactions between these cytokines and how their combined profile relates to disease activity. We have examined serum levels of IL-10, IL-12 and IL-1ra in a cohort of SLE patients obtained from the Queen Elizabeth Hospital, Birmingham in cross-sectional and, in a smaller group, longitudinal analyses. In the cross-sectional study, there were significant correlations between levels of the three cytokines. There were also significant correlations between levels of each cytokine and measures of disease activity. IL-10 levels correlated with ESR, anti-dsDNA antibody titres and C3D, IL-12 levels with anti-dsDNA antibody titres and IL-1ra levels with ESR, anti-dsDNA antibody titres and C3D. IL-1ra levels also correlated with CRP. Circulating IL-10 and IL-1ra levels were higher in patients with SLE than in normal controls, although in this study group they did not reach significance. Circulating IL-12 levels were, however, significantly higher in SLE compared to controls. This was true both in patients with active disease and those sampled during a quiescent phase. These data add to the evidence that cytokines such as IL-10, IL-12 and IL-1ra are important in SLE pathogenesis. In a retrospective study of serial serum samples from seven patients, we found two patients whose cytokine profile was very different from the rest of the group. In most patients normalized IL-10, IL-12 and IL-1ra levels mirrored BILAG scores closely, but in these two patients, IL-10, IL-12 and IL-1ra levels did not fluctuate with disease activity. It is possible that there is a subgroup of SLE patients whose cytokine profile could be an important indicator of their pathology. In order to confirm this and determine the frequency of such patients this study needs to be repeated with a much larger subject group. The coexistence of patient groups with different patterns of cytokine activity might explain conflicting reports of associations of levels of particular cytokines with SLE. As the observed differences could reflect different aetiologies of SLE, this information could reveal valuable endophenotypes for genetic and functional studies of SLE and might, ultimately, inform therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498048      PMCID: PMC1809203          DOI: 10.1111/j.1365-2249.2004.02607.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus.

Authors:  A W Gibson; J C Edberg; J Wu; R G Westendorp; T W Huizinga; R P Kimberly
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  Interleukin-1 receptor antagonist gene polymorphism, infectious burden, and coronary artery disease.

Authors:  Johann Auer; Robert Berent; Thomas Weber; Bernd Eber
Journal:  Clin Infect Dis       Date:  2002-06-01       Impact factor: 9.079

3.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  Immunoglobulin heavy chain constant-region gene polymorphism in systemic lupus erythematosus.

Authors:  A Kumar; C Martinez-Tarquino; A Maria-Forte; P Kumar; D Alarcon-Segovia; J Granados; J P Pandey; J Buxbaum; P H Schur
Journal:  Arthritis Rheum       Date:  1991-12

5.  TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus.

Authors:  A H Hajeer; J Worthington; E J Davies; M C Hillarby; K Poulton; W E Ollier
Journal:  Tissue Antigens       Date:  1997-03

6.  Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.

Authors:  R Dewberry; H Holden; D Crossman; S Francis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Association between a T cell receptor restriction fragment length polymorphism and systemic lupus erythematosus.

Authors:  J G Tebib; J Alcocer-Varela; D Alarcon-Segovia; P H Schur
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

9.  Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility.

Authors:  A H Fielder; M J Walport; J R Batchelor; R I Rynes; C M Black; I A Dodi; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-05

10.  Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.

Authors:  M J Nicklin; D E Hughes; J L Barton; J M Ure; G W Duff
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  14 in total

Review 1.  Foxp3, Regulatory T Cell, and Autoimmune Diseases.

Authors:  Jin-Hui Tao; Miao Cheng; Jiang-Ping Tang; Qin Liu; Fan Pan; Xiang-Pei Li
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

2.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  Insulin resistance in children with juvenile systemic lupus erythematosus and ınvestigation of the possibly responsible factors.

Authors:  Gürkan Tarçın; Hasan Karakaş; Sezgin Şahin; Hande Turan; Mehmet Yıldız; Yavuz Özer; Fatih Haşlak; Dilek Bingöl Aydın; Amra Adroviç; Kenan Barut; Özgür Kasapçopur; Oya Ercan
Journal:  Clin Rheumatol       Date:  2021-10-07       Impact factor: 2.980

Review 4.  Recent insights into the genetic basis of systemic lupus erythematosus.

Authors:  Ornella Josephine Rullo; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

5.  The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.

Authors:  Uri Sela; Amir Sharabi; Molly Dayan; Rami Hershkoviz; Edna Mozes
Journal:  Immunology       Date:  2008-11-24       Impact factor: 7.397

6.  B Cell in Autoimmune Diseases.

Authors:  Christiane S Hampe
Journal:  Scientifica (Cairo)       Date:  2012

7.  Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity.

Authors:  Xinfang Huang; Yanzhi Guo; Chunde Bao; Nan Shen
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

8.  Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.

Authors:  Zhenpeng Dai; Cameron J Turtle; Garrett C Booth; Stanley R Riddell; Theodore A Gooley; Anne M Stevens; Thomas Spies; Veronika Groh
Journal:  J Exp Med       Date:  2009-03-16       Impact factor: 14.307

9.  Altered AKT1 and MAPK1 gene expression on peripheral blood mononuclear cells and correlation with T-helper-transcription factors in systemic lupus erythematosus patients.

Authors:  Sonia Garcia-Rodriguez; Jose-Luis Callejas-Rubio; Norberto Ortego-Centeno; Esther Zumaquero; Raquel Ríos-Fernandez; Salvador Arias-Santiago; Pilar Navarro; Jaime Sancho; Mercedes Zubiaur
Journal:  Mediators Inflamm       Date:  2012-10-18       Impact factor: 4.711

10.  Serum IL-10 from systemic lupus erythematosus patients suppresses the differentiation and function of monocyte-derived dendritic cells.

Authors:  Zhida Sun; Rong Zhang; Huijuan Wang; Pengtao Jiang; Jiangquan Zhang; Mingshun Zhang; Lei Gu; Xiaofan Yang; Miaojia Zhang; Xiaohui Ji
Journal:  J Biomed Res       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.